Broadview Ventures Inc

"Data presented at AHA signifies the potential of this technology as a clinically viable non-invasive option for hemodynamic-guided heart failure management. We’re excited to move one step closer towards enabling a truly proactive monitoring solution for heart failure patients across the globe.” - Amit Gupta, co-founder and CEO Our Late-Breaking Science at #AHA24 is making news! Explore the findings that detail the performance of our AI-driven non-invasive technology. Read more here: https://lnkd.in/gb9z7aci #AHAChicago #Cardiosense #CardiacInnovation #NonInvasiveCare #AIinHealthcare With Liviu Klein, Omer Inan, Amit Gupta, Andrew Carek, Venu Ganti, and Arezou Azar, PhD - PMP, CSM

📣Announcing Scientific Sessions 2024 Late-Breaking Science 📣 Join us in November to experience the highest tier of scientific discovery and practice-changing educational content. 📍#AHA24, Chicago, IL, Nov 16-18

Is there a better way to treat patients with severe+ tricuspid regurgitation? We are excited to announce the first US patient treated with the DUO™ System as part of the TANDEM II Early Feasibility Study. The DUO™ System is a novel transcatheter valve that works in tandem with the native tricuspid valve to restore valve function while preserving the native valve apparatus. "The DUO™ System offers a unique benefit for patients suffering from TR as the device is designed to treat a broad patient population. The procedure is straightforward, leveraging standard interventional techniques and has the potential to accelerate transcatheter tricuspid therapy adoption by more physicians due to the system’s simplicity and scalability." Vinod Thourani Pradeep Yadav https://lnkd.in/gK9PfZg5  #CroiValve #DUO System #Tricuspid Regurgitation Learn more about the DUO System: https://croivalve.com Caution: The DUO System is an investigational device and not for sale in any geography.

📣 NEW PRESS RELEASE: IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer    We’re delighted to share that we have nominated ISM-001 as a development candidate for peripheral arterial disease (PAD). ISM-001 is a potential first-in-class, therapeutic antibody designed to neutralise VEGF-A165b, the anti-angiogenic VEGF-A splice isoform which acts as a brake on development of new blood vessels leading to chronic limb threatening ischaemia (CLTI). ISM-001 is being advanced into a program of pre-clinical studies necessary for gaining approval to enter first-in-human clinical trials.   We’re also excited to announce a strategic collaboration with Pfizer Ignite to accelerate preclinical and IND-enabling studies for ISM-001.    Our CEO, Jackie Turnbull, said: “Today’s announcement represents an important milestone for IsomAb and we continue to be encouraged by the potential of ISM-001 as a first-in-class treatment for patients with PAD, especially type 2 diabetics with CTLI at high risk of amputation. We appreciate the devastating loss of losing a limb and the impact on the lives of patients who have very limited treatment options. Given Pfizer’s strong commitment, extensive capabilities and deep expertise in developing new therapeutics, we are proud to partner with them to support the development of ISM-001, a transformative treatment for patients with PAD. We look forward to realising the full potential of ISM-001.” Read the full release: https://lnkd.in/grUzYW-y

📢 @Antag Therapeutics is pleased to announce #FDA IND clearance for AT-7687, our lead molecule for the treatment of #obesity.   AT-7687 is a peptide GIP receptor antagonist, designed for once-weekly subcutaneous administration. Preclinical studies have demonstrated that AT-7687 attenuates weight gain and enhances GLP-1-mediated weight loss while also improving lipid profiles, particularly LDL, independently of weight changes.   Our phase I clinical trial will evaluate the safety, tolerability, and pharmacokinetics of AT-7687, both as a monotherapy and in combination with #semaglutide, in healthy lean and healthy obese participants.   This is a significant milestone for #AntagTherapeutics, and we look forward to updating you as we progress AT-7687 through clinical development.   Read the full press release, linked in the comments below.   #clinicalupdate #INDclearance #GIP